{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T13:24:24Z","timestamp":1769520264159,"version":"3.49.0"},"reference-count":50,"publisher":"Zhejiang University Press","issue":"7","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["30800999"],"award-info":[{"award-number":["30800999"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["springerlink.com","zju.edu.cn"],"crossmark-restriction":true},"short-container-title":["J. Zhejiang Univ. Sci. B"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1631\/jzus.b1600143","type":"journal-article","created":{"date-parts":[[2017,7,17]],"date-time":"2017-07-17T06:31:52Z","timestamp":1500273112000},"page":"567-576","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Risk analysis of new oral anticoagulants for gastrointestinal bleeding and intracranial hemorrhage in atrial fibrillation patients: a systematic review and network meta-analysis"],"prefix":"10.1631","volume":"18","author":[{"given":"Wei-wei","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shen-jiang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"635","published-online":{"date-parts":[[2017,7,18]]},"reference":[{"issue":"8","key":"245_CR1","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","volume":"365","author":"J.H. Alexander","year":"2011","unstructured":"Alexander, J.H., Lopes, R.D., James, S., et al., 2011. Apixaban with antiplatelet therapy after acute coronary syndrome. N. Engl. J. Med., 365(8): 699\u2013708. http:\/\/dx.doi.org\/10.1056\/NEJMoa1105819","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"245_CR2","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","volume":"50","author":"C.B. Begg","year":"1994","unstructured":"Begg, C.B., Mazumdar, M., 1994. Operating characteristics of a rank correlation test for publication bias. Biometrics, 50(4): 1088\u20131101. http:\/\/dx.doi.org\/10.2307\/2533446","journal-title":"Biometrics"},{"issue":"1","key":"245_CR3","first-page":"40","volume":"5","author":"G. Biondi-Zoccai","year":"2013","unstructured":"Biondi-Zoccai, G., Malavasi, V., D'Ascenzo, F., et al., 2013. Comparative effectiveness of novel oral anticoagulants for atrial fibrillation: evidence from pair-wise and warfarin controlled network meta-analyses. HSR Proc. Intens. Care Cardiovasc. Anesth., 5(1): 40\u201354.","journal-title":"HSR Proc. Intens. Care Cardiovasc. Anesth."},{"issue":"21","key":"245_CR4","first-page":"2719","volume":"33","author":"A.J. Camm","year":"2012","unstructured":"Camm, A.J., Lip, G.Y., de Caterina, R., et al., 2012. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur. Heart J., 33(21): 2719\u20132747. http:\/\/dx.doi.org\/10.1093\/eurheartj\/ehs253","journal-title":"Developed with the special contribution of the European Heart Rhythm Association. Eur. Heart J."},{"issue":"10","key":"245_CR5","doi-asserted-by":"crossref","first-page":"477","DOI":"10.4321\/S0212-71992004001000003","volume":"21","author":"F.J. Candel","year":"2004","unstructured":"Candel, F.J., Matesanz, M., Cogolludo, F., et al., 2004. Prevalence of atrial fibrillation and relationed factors in a population in the centre Madrid. An. Med. Interna (Madrid), 21(10): 477\u2013482. https:\/\/doi.org\/10.4321\/S0212-71992004001000003","journal-title":"An. Med. Interna (Madrid)"},{"issue":"12","key":"245_CR6","first-page":"1486","volume":"70","author":"S. Chatterjee","year":"2013","unstructured":"Chatterjee, S., Sardar, P., Biondi-Zoccai, G., et al., 2013. New oral anticoagulants and the risk of intracranial hemorrhage: traditional and Bayesian meta-analysis and mixed treatment comparison of randomized trials of new oral anticoagulants in atrial fibrillation. JAMA Neurol., 70(12): 1486\u20131490. http:\/\/dx.doi.org\/10.1001\/jamaneurol.2013.4021","journal-title":"JAMA Neurol."},{"key":"245_CR7","first-page":"463767","volume":"2014","author":"W.C. Chen","year":"2014","unstructured":"Chen, W.C., Chen, Y.H., Hsu, P.I., et al., 2014. Gastrointestinal hemorrhage in warfarin anticoagulated patients: incidence, risk factor, management, and outcome. Bio-Med Res. Int., 2014:463767. http:\/\/dx.doi.org\/10.1155\/2014\/463767","journal-title":"Bio-Med Res. Int."},{"issue":"3","key":"245_CR8","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1160\/TH10-07-0451","volume":"105","author":"N. Chung","year":"2011","unstructured":"Chung, N., Jeon, H.K., Lien, L.M., et al., 2011. Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation. Thromb. Haemost., 105(3): 535\u2013544. http:\/\/dx.doi.org\/10.1160\/TH10-07-0451","journal-title":"Thromb. Haemost."},{"issue":"9526","key":"245_CR9","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","volume":"367","author":"S.J. Connolly","year":"2006","unstructured":"Connolly, S.J., Pogue, J., Hart, R., et al., 2006. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet, 367(9526): 1903\u20131912. http:\/\/dx.doi.org\/10.1016\/S0140-6736(06)68845-4","journal-title":"Lancet"},{"issue":"2","key":"245_CR10","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/0735-1097(91)90585-W","volume":"18","author":"S.J. Connolly","year":"1991","unstructured":"Connolly, S.J., Laupacis, A., Gent, M., et al., 1991. Canadian atrial fibrillation anticoagulation (CAFA) Study. J. Am. Coll. Cardiol., 18(2): 349\u2013355. http:\/\/dx.doi.org\/10.1016\/0735-1097(91)90585-W","journal-title":"J. Am. Coll. Cardiol."},{"issue":"20","key":"245_CR11","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMoa0901301","volume":"360","author":"S.J. Connolly","year":"2009","unstructured":"Connolly, S.J., Pogue, J., Hart, R.G., et al., 2009a. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N. Engl. J. Med., 360(20): 2066\u20132078. http:\/\/dx.doi.org\/10.1056\/NEJMoa0901301","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"245_CR12","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"S.J. Connolly","year":"2009","unstructured":"Connolly, S.J., Ezekowitz, M.D., Yusuf, S., et al., 2009b. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med., 361(12): 1139\u20131151. http:\/\/dx.doi.org\/10.1056\/NEJMoa0905561","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"245_CR13","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","volume":"364","author":"S.J. Connolly","year":"2011","unstructured":"Connolly, S.J., Eikelboom, J., Joyner, C., et al., 2011. Apixaban in patients with atrial fibrillation. N. Engl. J. Med., 364(9): 806\u2013817. http:\/\/dx.doi.org\/10.1056\/NEJMoa1007432","journal-title":"N. Engl. J. Med."},{"key":"245_CR14","unstructured":"Dias, S., Welton, N.J., Sutton, A.J., 2011. NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. Technical Support Document in Evidence Synthesis, No. TSD2. National Institute for Health and Clinical Excellence. http:\/\/core.ac.uk\/download\/pdf\/29025987.pdf"},{"issue":"5","key":"245_CR15","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1177\/0272989X12455847","volume":"33","author":"S. Dias","year":"2013","unstructured":"Dias, S., Welton, N.J., Sutton, A.J., et al., 2013. Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials. Med. Decis. Making, 33(5): 641\u2013656. http:\/\/dx.doi.org\/10.1177\/0272989X12455847","journal-title":"Med. Decis. Making"},{"issue":"5","key":"245_CR16","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/heartjnl-2013-304347","volume":"100","author":"A. Dogliotti","year":"2014","unstructured":"Dogliotti, A., Paolasso, E., Giugliano, R.P., 2014. Current and new oral antithrombotics in non-valvular atrial fibrillation: a network meta-analysis of 79 808 patients. Heart, 100(5): 396\u2013405. http:\/\/dx.doi.org\/10.1136\/heartjnl-2013-304347","journal-title":"Heart"},{"issue":"2","key":"245_CR17","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000068743","volume":"22","author":"D.A. Dulli","year":"2003","unstructured":"Dulli, D.A., Stanko, H., Levine, R.L., 2003. Atrial fibrillation is associated with severe acute ischemic stroke. Neuroepidemiology, 22(2): 118\u2013123. http:\/\/dx.doi.org\/10.1159\/000068743","journal-title":"Neuroepidemiology"},{"issue":"20","key":"245_CR18","first-page":"1406","volume":"327","author":"M.D. Ezekowitz","year":"1992","unstructured":"Ezekowitz, M.D., Bridgers, S.L., James, K.E., et al., 1992. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N. Engl. J. Med., 327(20): 1406\u20131412. http:\/\/dx.doi.org\/10.1056\/NEJM199211123272002","journal-title":"Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N. Engl. J. Med."},{"issue":"7","key":"245_CR19","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/CIRCULATIONAHA.106.177292","volume":"114","author":"V. Fuster","year":"2006","unstructured":"Fuster, V., Ryden, L.E., Cannom, D.S., et al., 2006. ACC\/ AHA\/ESC 2006 guidelines for the management of patients with atrial fibrillation. Circulation, 114(7): e257-e354. http:\/\/dx.doi.org\/10.1161\/circulationaha.106.177292","journal-title":"Circulation"},{"key":"245_CR20","first-page":"149","volume":"115","author":"B.J. Gersh","year":"2004","unstructured":"Gersh, B.J., Tsang, T.S., Seward, J.B., 2004. The changing epidemiology and natural history of nonvalvular atrial fibrillation: clinical implications. Trans. Am. Clin. Climatol. Assoc., 115:149\u2013159.","journal-title":"Trans. Am. Clin. Climatol. Assoc."},{"issue":"5","key":"245_CR21","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.ahj.2011.01.026","volume":"161","author":"C.M. Gibson","year":"2011","unstructured":"Gibson, C.M., Mega, J.L., Burton, P., et al., 2011. Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome. Am. Heart J., 161(5): 815\u2013821.e6. http:\/\/dx.doi.org\/10.1016\/j.ahj.2011.01.026","journal-title":"Am. Heart J."},{"issue":"3","key":"245_CR22","first-page":"406","volume":"46","author":"C.B. Giorda","year":"2014","unstructured":"Giorda, C.B., Nada, E., Tartaglino, B., 2014. Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature. Endocrine, 46(3): 406\u2013419. http:\/\/dx.doi.org\/10.1007\/s12020-014-0179-0","journal-title":"A systematic review of the literature. Endocrine"},{"issue":"22","key":"245_CR23","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"R.P. Giugliano","year":"2013","unstructured":"Giugliano, R.P., Ruff, C.T., Braunwald, E., et al., 2013. Edoxaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med., 369(22): 2093\u20132104. http:\/\/dx.doi.org\/10.1056\/NEJMoa1310907","journal-title":"N. Engl. J. Med."},{"key":"245_CR24","doi-asserted-by":"crossref","first-page":"640723","DOI":"10.1155\/2013\/640723","volume":"2013","author":"A. Gomez-Outes","year":"2013","unstructured":"Gomez-Outes, A., Terleira-Fernandez, A.I., Calvo-Rojas, G., et al., 2013. Dabigatran, rivaroxaban, or apixaban versus warfarin in patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis of subgroups. Thrombosis, 2013:640723. http:\/\/dx.doi.org\/10.1155\/2013\/640723","journal-title":"Thrombosis"},{"issue":"11","key":"245_CR25","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"C.B. Granger","year":"2011","unstructured":"Granger, C.B., Alexander, J.H., McMurray, J.J., et al., 2011. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med., 365(11): 981\u2013992. http:\/\/dx.doi.org\/10.1056\/NEJMoa1107039","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"245_CR26","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1001\/archinte.158.14.1513","volume":"158","author":"A.L. Gullov","year":"1998","unstructured":"Gullov, A.L., Koefoed, B.G., Petersen, P., et al., 1998. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch. Intern. Med., 158(14): 1513\u20131521. http:\/\/dx.doi.org\/10.1001\/archinte.158.14.1513","journal-title":"Arch. Intern. Med."},{"issue":"7215","key":"245_CR27","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1136\/bmj.319.7215.958","volume":"319","author":"B.S. Hellemons","year":"1999","unstructured":"Hellemons, B.S., Langenberg, M., Lodder, J., et al., 1999. Primary prevention of arterial thromboembolism in nonrheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin. BMJ, 319(7215): 958\u2013964. http:\/\/dx.doi.org\/10.1136\/bmj.319.7215.958","journal-title":"BMJ"},{"key":"245_CR28","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"J. Higgins","year":"2006","unstructured":"Higgins, J., Green, S., 2006. Cochrane Handbook for Systematic Reviews of Interventions. John Wiley & Sons, Ltd., Chichester, UK."},{"issue":"1","key":"245_CR29","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1053\/j.gastro.2013.02.041","volume":"145","author":"I.L. Holster","year":"2013","unstructured":"Holster, I.L., Valkhoff, V.E., Kuipers, E.J., et al., 2013. New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis. Gastroenterology, 145(1): 105\u2013112.e15. http:\/\/dx.doi.org\/10.1053\/j.gastro.2013.02.041","journal-title":"Gastroenterology"},{"issue":"9","key":"245_CR30","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1253\/circj.CJ-12-0454","volume":"76","author":"M. Hori","year":"2012","unstructured":"Hori, M., Matsumoto, M., Tanahashi, N., et al., 2012. Rivaroxaban vs.warfarin in Japanese patients with atrial fibrillation. Circ. J., 76(9): 2104\u20132111. http:\/\/dx.doi.org\/10.1253\/circj.CJ-12-0454","journal-title":"Circ. J."},{"issue":"4","key":"245_CR31","first-page":"295","volume":"34","author":"D.Y. Hu","year":"2006","unstructured":"Hu, D.Y., Zhang, H.P., Sun, Y.H., et al., 2006. The randomized study of efficiency and safety of antithrombotic therapy in nonvalvular atrial fibrillation: warfarin compared with aspirin. Chin. J. Cardiol., 34(4): 295\u2013298 (in Chinese).","journal-title":"Chin. J. Cardiol."},{"key":"245_CR32","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/1741-7015-11-159","volume":"11","author":"J.P. Jansen","year":"2013","unstructured":"Jansen, J.P., Naci, H., 2013. Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers. BMC Med., 11:159. http:\/\/dx.doi.org\/10.1186\/1741-7015-11-159","journal-title":"BMC Med."},{"issue":"23","key":"245_CR33","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1161\/CIR.0000000000000040","volume":"130","author":"C.T. January","year":"2014","unstructured":"January, C.T., Wann, L.S., Alpert, J.S., et al., 2014. 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: executive summary. Circulation, 130(23): 2071\u20132104. http:\/\/dx.doi.org\/10.1161\/CIR.0000000000000040","journal-title":"Circulation"},{"issue":"9","key":"245_CR34","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1111\/j.1538-7836.2011.04432.x","volume":"9","author":"M. Levi","year":"2011","unstructured":"Levi, M., Eerenberg, E., Kamphuisen, P.W., 2011. Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. J. Thromb. Haemost., 9(9): 1705\u20131712. http:\/\/dx.doi.org\/10.1111\/j.1538-7836.2011.04432.x","journal-title":"J. Thromb. Haemost."},{"issue":"10","key":"245_CR35","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1161\/01.STR.0000240508.28625.2c","volume":"37","author":"R. Luengo-Fernandez","year":"2006","unstructured":"Luengo-Fernandez, R., Gray, A.M., Rothwell, P.M., 2006. Population-based study of determinants of initial secondary care costs of acute stroke in the United Kingdom. Stroke, 37(10): 2579\u20132587. http:\/\/dx.doi.org\/10.1161\/01.STR.0000240508.28625.2c","journal-title":"Stroke"},{"issue":"16","key":"245_CR36","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1002\/sim.1201","volume":"21","author":"T. Lumley","year":"2002","unstructured":"Lumley, T., 2002. Network meta-analysis for indirect treatment comparisons. Stat. Med., 21(16): 2313\u20132324. http:\/\/dx.doi.org\/10.1002\/sim.1201","journal-title":"Stat. Med."},{"issue":"9586","key":"245_CR37","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0140-6736(07)61233-1","volume":"370","author":"J. Mant","year":"2007","unstructured":"Mant, J., Hobbs, F.D., Fletcher, K., et al., 2007. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet, 370(9586): 493\u2013503. http:\/\/dx.doi.org\/10.1016\/S0140-6736(07)61233-1","journal-title":"Lancet"},{"issue":"1","key":"245_CR38","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","volume":"366","author":"J.L. Mega","year":"2012","unstructured":"Mega, J.L., Braunwald, E., Wiviott, S.D., et al., 2012. Rivaroxaban in patients with a recent acute coronary syndrome. N. Engl. J. Med., 366(1): 9\u201319. http:\/\/dx.doi.org\/10.1056\/NEJMoa1112277","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"245_CR39","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1253\/circj.CJ-10-1183","volume":"75","author":"S. Ogawa","year":"2011","unstructured":"Ogawa, S., Shinohara, Y., Kanmuri, K., 2011. Safety and efficacy of the oral direct factor Xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation. Circ. J., 75(8): 1852\u20131859. http:\/\/dx.doi.org\/10.1253\/circj.CJ-10-1183","journal-title":"Circ. J."},{"issue":"10","key":"245_CR40","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"M.R. Patel","year":"2011","unstructured":"Patel, M.R., Mahaffey, K.W., Garg, J., et al., 2011. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med., 365(10): 883\u2013891. http:\/\/dx.doi.org\/10.1056\/NEJMoa1009638","journal-title":"N. Engl. J. Med."},{"issue":"8631","key":"245_CR41","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0140-6736(89)91200-2","volume":"333","author":"P. Petersen","year":"1989","unstructured":"Petersen, P., Boysen, G., Godtfredsen, J., et al., 1989. Placebocontrolled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK Study. Lancet, 333(8631): 175\u2013179. http:\/\/dx.doi.org\/10.1016\/S0140-6736(89)91200-2","journal-title":"Lancet"},{"issue":"9921","key":"245_CR42","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","volume":"383","author":"C.T. Ruff","year":"2014","unstructured":"Ruff, C.T., Giugliano, R.P., Braunwald, E., et al., 2014. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet, 383(9921): 955\u2013962. http:\/\/dx.doi.org\/10.1016\/S0140-6736(13)62343-0","journal-title":"Lancet"},{"issue":"2","key":"245_CR43","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1161\/01.STR.0000199147.30016.74","volume":"37","author":"R.L. Sacco","year":"2006","unstructured":"Sacco, R.L., Adams, R., Albers, G., et al., 2006. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack. Stroke, 37(2): 577\u2013617. http:\/\/dx.doi.org\/10.1161\/01.STR.0000199147.30016.74","journal-title":"Stroke"},{"issue":"2","key":"245_CR44","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1161\/01.STR.0000198839.61112.ee","volume":"37","author":"H. Sato","year":"2006","unstructured":"Sato, H., Ishikawa, K., Kitabatake, A., et al., 2006. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. Stroke, 37(2): 447\u2013451. http:\/\/dx.doi.org\/10.1161\/01.STR.0000198839.61112.ee","journal-title":"Stroke"},{"issue":"7640","key":"245_CR45","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1136\/bmj.39456.688333.BE","volume":"336","author":"K.B. Slot","year":"2008","unstructured":"Slot, K.B., Berge, E., Dorman, P., et al., 2008. Impact of functional status at six months on long term survival in patients with ischaemic stroke: prospective cohort studies. BMJ, 336(7640): 376\u2013379. http:\/\/dx.doi.org\/10.1136\/bmj.39456.688333.BE","journal-title":"BMJ"},{"key":"245_CR46","volume-title":"WinBUGS User Manual","author":"D. Spiegelhalter","year":"2004","unstructured":"Spiegelhalter, D., Thomas, A., Best, N., 2004. WinBUGS User Manual. MRC Biostatistics Unit, Cambridge."},{"issue":"9","key":"245_CR47","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/sim.1761","volume":"23","author":"M.J. Sweeting","year":"2004","unstructured":"Sweeting, M.J., Sutton, A.J., Lambert, P.C., 2004. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat. Med., 23(9): 1351\u20131375. http:\/\/dx.doi.org\/10.1002\/sim.1761","journal-title":"Stat. Med."},{"issue":"22","key":"245_CR48","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1056\/NEJM199011293232201","volume":"323","author":"The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators","year":"1990","unstructured":"The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators, 1990. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N. Engl. J. Med., 323(22): 1505\u20131511. http:\/\/dx.doi.org\/10.1056\/NEJM199011293232201","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"245_CR49","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1253\/circj.CJ-11-1140","volume":"76","author":"T. Yamashita","year":"2012","unstructured":"Yamashita, T., Koretsune, Y., Yasaka, M., et al., 2012. Randomized, multicenter, warfarin-controlled phase IIstudy of edoxaban in Japanese patients with non-valvular atrial fibrillation. Circ. J., 76(8): 1840\u20131847. http:\/\/dx.doi.org\/10.1253\/circj.CJ-11-1140","journal-title":"Circ. J."},{"issue":"4","key":"245_CR50","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1631\/jzus.B1201007","volume":"13","author":"S. Zhang","year":"2012","unstructured":"Zhang, S., 2012. Clinical considerations of anticoagulation therapy for patients with atrial fibrillation. J. Zhejiang Univ.-Sci. B (Biomed. & Biotechnol.), 13(4): 609\u2013615. http:\/\/dx.doi.org\/10.1631\/jzus.B1201007","journal-title":"J. Zhejiang Univ.-Sci. B (Biomed. & Biotechnol.)"}],"container-title":["Journal of Zhejiang University-SCIENCE B"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1631\/jzus.B1600143.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1631\/jzus.B1600143\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1631\/jzus.B1600143.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,12,13]],"date-time":"2017-12-13T01:51:39Z","timestamp":1513129899000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1631\/jzus.B1600143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":50,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["245"],"URL":"https:\/\/doi.org\/10.1631\/jzus.b1600143","relation":{},"ISSN":["1673-1581","1862-1783"],"issn-type":[{"value":"1673-1581","type":"print"},{"value":"1862-1783","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"http:\/\/orcid.org\/0000-0001-8310-2632","URL":"http:\/\/orcid.org\/0000-0001-8310-2632","order":0,"name":"name","label":"Wei-wei XU","group":{"name":"orcid","label":"ORCID"}},{"value":"http:\/\/orcid.org\/0000-0003-3789-7854","URL":"http:\/\/orcid.org\/0000-0003-3789-7854","order":1,"name":"name","label":"Tao WU","group":{"name":"orcid","label":"ORCID"}},{"value":"doi:10.1631\/jzus.B1201007","URL":"http:\/\/www.zju.edu.cn\/jzus\/article.php?doi=10.1631\/jzus.B1201007","order":0,"name":"name","label":"Clinical considerations of...","group":{"name":"name","label":"Similar articles"}},{"value":"2016-03-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-10-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-06-16","order":2,"name":"crosschecked","label":"Crosschecked","group":{"name":"publication_history","label":"Publication History"}},{"value":"Article","order":0,"name":"content_type","group":{"name":"content_type","label":"Content Type"}},{"value":"\u00a9 Zhejiang University and Springer-Verlag Berlin Heidelberg 2017","order":0,"name":"copyright","group":{"name":"copyright","label":"Copyright"}}]}}